A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

The most recent U.S. Food and Drug Administration inspection of Thermo Fisher’s Greenville plant in May identified manufacturing issues for the respiratory syncytial virus drug Beyfortus, a preventive ...

With almost EUR3 billion in the first nine months, our launches have become significant contributors to Sanofi's accelerated ...

Beyfortus Sales Projection: Expected to reach around ... Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales ...

Beyfortus, thanks to the approval of additional production capacity, according to Sanofi. The group benefited from the strength of Dupixent, which treats a number of diseases linked to immune system ...

"Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et ...

Growth at the vaccines business was driven in part by the rollout of Beyfortus, a shot that protects babies from respiratory syncytial virus (RSV). Merck also has a rival monoclonal antibody shot in ...